The frequency and intensity of topical pimecrolimus treatment in children with physician-confirmed mild to moderate atopic dermatitis

Pediatric Dermatology

Volumn 26, Issue 6, 2009, Pages 682-687

  Kapoor, Roger ^a   Hoffstad, Ole ^b   Bilker, Warren ^b   Margolis, David J ^b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PIMECROLIMUS; TACROLIMUS;

ADOLESCENT; ARTICLE; ATOPIC DERMATITIS; CHILD; CLINICAL TRIAL; COMMUNITY; DISEASE CONTROL; DRUG SAFETY; DRUG USE; DRUG UTILIZATION; FEMALE; FOLLOW UP; HISTORY; HUMAN; INFORMATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PRIORITY JOURNAL; QUESTIONNAIRE;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADRENAL CORTEX HORMONES; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; PRODUCT SURVEILLANCE, POSTMARKETING; QUESTIONNAIRES; REGISTRIES; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME; UNITED STATES;

EID: 73449127609     PISSN: 07368046     EISSN: 15251470     Source Type: Journal    
DOI: 10.1111/j.1525-1470.2009.01013.x     Document Type: Article

References (22)

1. Akdis CA, Akdis M, Bieber T et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy 2006 61 : 969 987. (Pubitemid 44024897)
2. Charman CR, Williams HC. Epidemiology. In : Bieber T, Leung DYM, eds. Atopic dermatitis, 1st edn. New York : Marcel Dekker, Inc., 2002 : 21 42.
3. Asher MI, Montefort S, Bjorksten B et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006 368 : 733 743.
4. Illi S, von Mutius E, Lau S et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol 2004 113 : 925 931.
5. Bickers DR, Lim HW, Margolis D et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol 2006 55 : 490 500.
6. Kapoor R, Menon C, Hoffstad O et al. The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. J Am Acad Dermatol 2008 58 : 68 73.
7. Jourdan-Da SN, Perel Y, Mechinaud F et al. Infectious diseases in the first year of life, perinatal characteristics and childhood acute leukemia. Br J Cancer 2004 90 : 139 145.
8. Mehrany K, El-Azhary RA, Bouwhuis SA et al. Cutaneous T-cell lymphoma and atopy: is there an association? Br J Dermatol 2003 149 : 1013 1017.
9. Bernard LA, Eichenfield LF. Topical immunomodulators for atopic dermatitis. Curr Opin Pediatr 2002 14 : 414 418.
10. Elidel®. Pimecrolimus 1% cream [prescribing information]. East Hanover, NJ : Novartis Pharmaceuticals Corp., 2006.
11. USP DI, ed 23. Greenwood Village, CO : Micromedex Thomson Healthcare, 2003.
12. Qureshi AA, Fischer MA. Topical calcineurin inhibitors for atopic dermatitis. Arch Dermatol 2006 142 : 633 637.
13. Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002 47 : 1 17.
14. Ormerod AD. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Br J Dermatol 2005 153 : 701 705.
15. Arellano FM, Wentworth CE, Arana A et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007 127 : 808 816.
16. Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007 214 : 289 295.
17. Lasser KE, Seger DL, Yu T et al. Adherence to black box warnings for prescription medications in outpatients. Arch Intern Med 2006 166 : 338 344.
18. Wagner AK, Chan KA, Dashevsky I et al. FDA drug prescribing warnings: is the back box half empty or half full? Pharmacoepidemiol Drug Saf 2006 15 : 369 386.
19. Purvis DJ, Thompson JM, Clark PM et al. Risk factors for atopic dermatitis in New Zealand children at 3.5 years of age. Br J Dermatol 2005 152 : 742 749.
20. Nafstad P, Magnus P, Gaarder PI et al. Exposure to pets and atopy-related diseases in the first 4 years of life. Allergy 2001 56 : 307 312.
21. Williams HC, Burney PG, Hay RJ et al. The UK working patry's diagnostic criteria for atopic dermatitis, I: derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol 1994 131 : 383 396.
22. Gustafsson D, Sjoberg O, Foucard T. Development of allergies and asthma in infants and young children with atopic dermatitis - a prospective follow-up to 7 years of age. Allergy 2000 55 : 240 245.